The biology behind the new therapies for SLE

J. Ermann, B. L. Bermas

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Background: Systemic lupus erythematosus (SLE) is a heterogenous disease with complex pathogenesis. Aim: In this review, we summarise recent progress in the understanding of SLE pathogenesis and discuss implications for the treatment of SLE patients using standard and experimental medications. Conclusions: The discovery that Toll-like receptor signalling and interferon-α abundance are central elements of the disease process has led to a new appreciation for hydroxychloroquine as an essential baseline medication. Although much needs to be learned, modulation of the immune system via B-cell depletion is entering clinical practice. Mycophenolate mofetil is an effective and safer alternative to cyclophosphamide for many patients with lupus nephritis. Several other therapeutic approaches are at various stages of preclinical and clinical development. These include anticytokine therapies, co-stimulatory blockade, antigen-specific immune modulation and haematopoietic stem cell transplantation.

Original languageEnglish (US)
Pages (from-to)2113-2119
Number of pages7
JournalInternational Journal of Clinical Practice
Volume61
Issue number12
DOIs
StatePublished - Dec 1 2007

Fingerprint

Systemic Lupus Erythematosus
Mycophenolic Acid
Hydroxychloroquine
Lupus Nephritis
Toll-Like Receptors
Hematopoietic Stem Cell Transplantation
Cyclophosphamide
Interferons
Immune System
B-Lymphocytes
Therapeutics
Antigens

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The biology behind the new therapies for SLE. / Ermann, J.; Bermas, B. L.

In: International Journal of Clinical Practice, Vol. 61, No. 12, 01.12.2007, p. 2113-2119.

Research output: Contribution to journalReview article

@article{d299715e92424ff8b6b8dfd117c468c2,
title = "The biology behind the new therapies for SLE",
abstract = "Background: Systemic lupus erythematosus (SLE) is a heterogenous disease with complex pathogenesis. Aim: In this review, we summarise recent progress in the understanding of SLE pathogenesis and discuss implications for the treatment of SLE patients using standard and experimental medications. Conclusions: The discovery that Toll-like receptor signalling and interferon-α abundance are central elements of the disease process has led to a new appreciation for hydroxychloroquine as an essential baseline medication. Although much needs to be learned, modulation of the immune system via B-cell depletion is entering clinical practice. Mycophenolate mofetil is an effective and safer alternative to cyclophosphamide for many patients with lupus nephritis. Several other therapeutic approaches are at various stages of preclinical and clinical development. These include anticytokine therapies, co-stimulatory blockade, antigen-specific immune modulation and haematopoietic stem cell transplantation.",
author = "J. Ermann and Bermas, {B. L.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1111/j.1742-1241.2007.01528.x",
language = "English (US)",
volume = "61",
pages = "2113--2119",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - The biology behind the new therapies for SLE

AU - Ermann, J.

AU - Bermas, B. L.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Background: Systemic lupus erythematosus (SLE) is a heterogenous disease with complex pathogenesis. Aim: In this review, we summarise recent progress in the understanding of SLE pathogenesis and discuss implications for the treatment of SLE patients using standard and experimental medications. Conclusions: The discovery that Toll-like receptor signalling and interferon-α abundance are central elements of the disease process has led to a new appreciation for hydroxychloroquine as an essential baseline medication. Although much needs to be learned, modulation of the immune system via B-cell depletion is entering clinical practice. Mycophenolate mofetil is an effective and safer alternative to cyclophosphamide for many patients with lupus nephritis. Several other therapeutic approaches are at various stages of preclinical and clinical development. These include anticytokine therapies, co-stimulatory blockade, antigen-specific immune modulation and haematopoietic stem cell transplantation.

AB - Background: Systemic lupus erythematosus (SLE) is a heterogenous disease with complex pathogenesis. Aim: In this review, we summarise recent progress in the understanding of SLE pathogenesis and discuss implications for the treatment of SLE patients using standard and experimental medications. Conclusions: The discovery that Toll-like receptor signalling and interferon-α abundance are central elements of the disease process has led to a new appreciation for hydroxychloroquine as an essential baseline medication. Although much needs to be learned, modulation of the immune system via B-cell depletion is entering clinical practice. Mycophenolate mofetil is an effective and safer alternative to cyclophosphamide for many patients with lupus nephritis. Several other therapeutic approaches are at various stages of preclinical and clinical development. These include anticytokine therapies, co-stimulatory blockade, antigen-specific immune modulation and haematopoietic stem cell transplantation.

UR - http://www.scopus.com/inward/record.url?scp=35948981101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948981101&partnerID=8YFLogxK

U2 - 10.1111/j.1742-1241.2007.01528.x

DO - 10.1111/j.1742-1241.2007.01528.x

M3 - Review article

C2 - 17997810

AN - SCOPUS:35948981101

VL - 61

SP - 2113

EP - 2119

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 12

ER -